Search results
12 lip 2024 · Remdesivir (Veklury) reduced the risk of hospitalization and death by 87% in unvaccinated outpatients with COVID-19 who are at higher risk of severe disease. A 3-day course of intravenous remdesivir initiated within 7 days of symptom onset is the second preferred treatment option after ritonavir-boosted nirmatrelvir for adults and pediatric ...
16 lut 2022 · The early use of remdesivir in outpatients with Covid-19 who are at high risk for disease progression reduces the risk of hospitalization and death, as reported in our double-blind,...
29 lip 2024 · This topic will address the management of adult patients with acute COVID-19 in the outpatient setting, including self-care advice, telehealth and outpatient management, and post-hospital discharge care.
Recommendation 16: Among patients (ambulatory or hospitalized) with mild-to-moderate COVID-19 at high risk for progression to severe disease, the IDSA guideline panel suggests remdesivir initiated within seven days of symptom onset rather than no remdesivir.
22 gru 2021 · Remdesivir improves clinical outcomes in patients hospitalized with moderate-to-severe coronavirus disease 2019 (Covid-19). Whether the use of remdesivir in symptomatic, nonhospitalized patients...
24 paź 2024 · Remdesivir is the only antiviral approved for treatment of persons hospitalized for COVID-19. This supplement presents new information from real-world coho ... Comparative safety of different antibiotic regimens for the treatment of outpatient community-acquired pneumonia among otherwise healthy adults . Management of vulnerable patients ...
A clear clinical benefit of remdesivir for outpatient treatment of COVID-19 was shown in PINETREE, a randomized, double-blind, placebo-controlled trial comparing 3-day intravenously administered remdesivir to placebo in nonhospitalized patients aged ≥ 12 years with COVID-19, symptom onset ≤ 7 days before randomization, and ≥ 1 risk factor ...
